Every life science CEO believes they have a platform. Most have a portal. The difference between the two is not cosmetic. It is structural. And the companies that understand the difference are pulling away from the pack in ways that are becoming impossible to ignore.
What is a platform, really?
Every life science CEO I meet has a platform story. They all believe they have one. A portal, they will tell you, with a portal login, a portal dashboard, and a portal that feels like a platform if you squint at it hard enough. The reality is that most of what passes for platform strategy in life sciences today is a glorified catalog with a login button. It is a portal that looks like a platform if you squint at it hard enough. But the difference between a portal and a platform is not cosmetic. It is structural. And the companies that get this distinction right are pulling away from the pack in ways that are becoming impossible to ignore.
Most life science companies call any digital interface a platform. A customer portal with a login is not a platform. A branded ordering system is not a platform. A portal that sits on top of a CRM is not a platform. A platform creates a structured environment where multiple actors can participate, exchange value, and create outcomes that none of them could achieve alone. The difference between a portal and a platform is not cosmetic. It is structural. And most life science companies are building portals and calling them platforms.
The research that underpins this framework is straightforward. A genuine platform is defined by two mechanisms: crowdsourcing (the platform draws value in from a diverse set of participants) and crowdsending (the platform sends value back out to a diverse set of participants). When both mechanisms are present, the platform creates an ecosystem. When only one is present, you have a tool. When neither is present, you have a brochure.
The distinction matters because it determines what kind of relationship you can build with your ecosystem. A portal optimizes a transaction. A platform creates a relationship. And in life sciences, where the relationship is the product, this distinction is the difference between a cost centre and a competitive advantage.
The Four Modes
Not all platforms are created equal. The most useful way to think about platform strategy in life sciences is not through the lens of technology stack or feature parity, but through the lens of relationship depth and value co-creation intensity. This gives us four distinct modes.
| Actor | Mode 1: Utility | Mode 2: Advisor | Mode 3: Co-Creator | Mode 4: Companion |
|---|---|---|---|---|
| Brand | H Give / L Take | H Give / M Take | M Give / H Take | M Give / H Take |
| HCPs | L Give / H Take | M Give / H Take | H Give / H Take | H Give / H Take |
| Patients | L Give / M Take | M Give / H Take | M Give / H Take | H Give / H Take |
| Hospitals | L Give / M Take | M Give / H Take | H Give / H Take | H Give / H Take |
| Payers | L Give / L Take | M Give / M Take | M Give / H Take | H Give / H Take |
| 3rd Party Services | L Give / L Take | L Give / M Take | H Give / M Take | H Give / H Take |
“The platform that wins is not the one with the most features. It is the one that becomes indispensable to the most actors.” The brand that wins is not the one with the most features. It is the one that becomes indispensable to the most actors.
Four real cases, four different paths
Abbott FreeStyle Libre / LibreView is the most complete example of the journey from instrument to companion in the sector. The FreeStyle Libre CGM system is the instrument. LibreView is the platform layer that connects devices, clinicians, and patients. The system has demonstrated measurable clinical outcomes: a 0.6 percentage point reduction in HbA1c and 1.3 hours more time in range per day for users. In Southeast Asia, the partnership with Singapore’s Health Promotion Board (HPB) DigiCoach programme is the proof point that this model works at scale in the region.
Novo Nordisk is building the most aggressive platform play in the industry through Kakao Healthcare in Korea, Tencent Health in China, and a series of digital health partnerships across Asia-Pacific. The company reported 122% growth in obesity care in APAC in 2025, and the platform layer is the primary reason. The platform is not just a distribution channel. It is the mechanism through which Novo Nordisk captures the entire obesity care journey.
Roche / AstraZeneca are building the most sophisticated co-creation platforms in the industry through their navify algorithms and AI-driven clinical decision support. The navify platform now hosts over 100 algorithms and algorithms across oncology, cardiology, and radiology. The strategic value is not in the algorithm. It is in the network effect that comes from having the largest repository of clinical data and decision support in the field.
What separates movers from laggards
The data is clear. The companies that capture this growth will not be the ones with the best product portfolio. They will be the ones with the best platform.
The four structural lessons are clear. First, platform maturity compounds. A Utility platform that evolves into an Advisor platform creates more value than the sum of its parts. Second, channel expansion is the single biggest growth lever. Third, data is the defensible asset. And fourth, the brand that wins is not the one with the best product. It is the one that becomes indispensable to the most actors in the ecosystem.
The companies that build platforms that capture this growth will be the ones that understand that the platform is not the product. The platform is the strategy.
DR. AIDEA - Ideas In Life & healthcare 